BACKGROUNDER: PROTECTING THE LEGAL RIGHTS OF GENERIC DRUG VICTIMS

Two recent state court decisions have restored the legal rights of patients harmed by generic drugs whose rights were extinguished in 2011. These decisions must be protected.*

Introduction

Since 2011, consumers who take generic drugs and are injured due to an unsafe, inaccurate or outdated label have no recourse in court. Yet those injured by the brand-name version of the same drug have their full legal rights. This absurd and unfair result was caused by a U.S. Supreme Court decision, which could be corrected either by Congress or the Food and Drug Administration (FDA). However, as a result of industry lobbying pressure, neither Congress nor the FDA has done so to date.

Now, high courts in two states – California and Massachusetts – have issued decisions based on state tort law that rectify this gross injustice in ways that make legal and practical sense for residents in those states. However, there are indications that the drug industry may respond politically to these recent cases by pushing either federal legislation or a new federal rule to undermine them. Such special interests may go so far as to push for a new federal liability scheme where no one – whether harmed by a generic or a brand-name drug – has any legal rights at all.1

Rights of Generic Drug Victims

In 2011, in the case PLIVA vs. Mensing,2 the U.S. Supreme Court immunized the generic drug industry from liability for injuries caused by a drug’s unsafe warning label, even if the manufacturer knows that label to be inaccurate and out-of-date. The Court noted that FDA regulations specify that generic drug companies are responsible only for ensuring that their warning labels are the same as the brand-name labels.3 The Court reasoned that since generic drug companies cannot independently change their warning labels, they cannot be held legally responsible when the labels are inadequate.4

* Thanks to New York Law School student Allyson Balcolm who contributed to this Backgrounder. For more information contact Joanne Doroshow, Executive Director, Center for Justice & Democracy, joanned@centerjd.org.
The result has been a two-tiered system of justice in America, succinctly described by Justice Sonia Sotomayor in her dissent in *Mensing* when she said the decision would result in “so many absurd consequences that I cannot fathom that Congress would have intended….” Specifically, “[a] drug consumer’s right to compensation for inadequate warnings now turns on the happenstance of whether her pharmacist filled her prescription with a brand-name drug or a generic. If a consumer takes a brand-name drug, she can sue the manufacturer for inadequate warnings under our opinion in *Wyeth*. If, however, she takes a generic drug, as occurs 75 percent of the time, she now has no right to sue.”

Federal legislation to correct the situation, which even the Court suggested was “bizarre,” was immediately introduced but failed to gain momentum. During the Obama administration, the FDA tried to do the same with a new proposed rule establishing new safety responsibilities for generic drug companies. However, the rule was never finalized, and it is unlikely to be issued under the Trump administration.

**Recent State Court Decisions**

Two recent state Supreme Court decisions have established a state tort remedy for patients injured by generic drugs in ways that make legal and practical sense for residents in those states.

In December 2017, in the case *T.H. v. Novartis*, the California Supreme Court ruled that a brand-name drug company may be liable for injuries caused by an unsafe generic drug warning label. The ruling was grounded in the FDA’s regulatory scheme, which provides that only a brand-name company – and not a generic company – has the power and authority to change a drug safety label. As explained by Leslie Brueckner, counsel for the plaintiffs, “Writing for a unanimous Court on this point, Justice Cuellar held that, because generic manufacturers are ‘required to follow the brand-name manufacturer’s label to the letter,’ a brand-name manufacturer ‘owes a duty of reasonable care in ensuring that the label includes appropriate warnings, regardless of whether the end user has been dispensed the brand-name drug or its generic bioequivalent.’” In addition, the decision “gives consumers of generic drugs the right to seek justice for their injuries. It will also protect public health and safety, by giving brand-name manufacturers a strong incentive to update their labels when new risks emerge after their drugs go generic.”

Similarly, in its March 2018 decision in *Rafferty v. Merck*, the Massachusetts Supreme Court ruled that brand-name drug companies can be sued for recklessness from inadequate warning labels on generic versions of their drugs. The Court maintained that “public policy is not served if generic drug consumers have no remedy for the failure of a brand-name manufacturer to warn in cases where such failure exceeds ordinary negligence, and rises to the level of recklessness.” According to the Court, “This recklessness standard strikes the most appropriate balance between competing public policy interests, limiting liability for brand-name manufacturers while also providing remedies for the most serious injuries and deterring the most dangerous forms of conduct.”

As Leslie Brueckner noted after the *Novartis* ruling, such cases not only provide important remedies for the vast majority of drug consumers whose rights were eliminated in 2011 but will also “make America a much safer place.” That’s because the brand-name companies, and only
the brand name companies, write the safety information that appears on both the brand-name and generic drug labels. If this information is outdated or incorrect, people will be hurt or killed. It is the “risk of tort liability [that] creates an incentive for drug companies to change their labels when new risks emerge…. [W]hen drug companies know they can’t be sued for negligent misrepresentation, all bets are off. Unless there’s a risk of liability in the courts, there’s little incentive for drug companies like Novartis to change their labels to warn of newly discovered risks. Today’s decision creates that much-needed incentive and, as a result, drugs will be much safer for everyone.”

Stakeholder Reaction

Not surprisingly, the drug industry, which generally seeks minimal responsibility and liability exposure, reacted negatively to these decisions. On February 9, 2018 – less than two months after the Novartis ruling – the industry-friendly Congressional Civil Justice Academy at George Mason University’s law school signaled the industry’s possible political response by holding a Senate event featuring Leslie Brueckner and attorney Phil Goldberg of Shook Hardy & Bacon, which represents the drug industry in its “tort reform” lobbying practice.

Goldberg suggested, among other things, that the federal government (i.e., the FDA) should take care of all drug safety problems. That would mean state tort rights of injured drug consumers would essentially be eliminated, providing the entire pharmaceutical industry with immunity. This is similar to the drug industry’s response to the Obama administration’s FDA proposed rule in 2015, when brand and generic companies argued that they should be permitted to escape responsibility for independently fixing labels even if they know the labels are inaccurate or out-of-date, placing exclusive safety responsibility on the FDA. More specifically, no injured person – whether harmed by a generic or a brand-name drug label – would have any legal rights to hold a company accountable in court or obtain compensation for injuries. That position was strongly opposed by a large number of consumer, patient safety and legal organizations not to mention members of the public and individual victims who have suffered as a result of unsafe drugs.

Goldberg and the industry’s position also stands in stark contrast to other U.S. Supreme Court rulings, including the 2009 case Wyeth v. Levine, where the Court ruled that brand-name drug companies should not be immune from liability for injuring or killing patients. The Court explained that the “FDA has limited resources to monitor the 11,000 drugs on the market and manufacturers have superior access to information about their drugs, especially in the post-marketing phase as new risks emerge,” and the “FDA long maintained that state law offers an additional, and important, layer of consumer protection that complements FDA regulation.” Further, in terms of state tort law, the Court said that “[s]tate tort suits uncover unknown drug hazards and provide incentives for drug manufacturers to disclose safety risks promptly” and that such suits “serve a distinct compensatory function that may motivate injured persons to come forward with information.”

Notes

1 This is precisely what the industry lobbied the FDA to do in 2015. See, e.g., Alliance for Justice et al., “Comments to FDA on Generic Drugs and Industry Proposal,” April 20, 2015, https://centerjd.org/content/comments-fda-generic-drugs-and-industry-proposal
4 Id. at 2577-8.
5 Id. at 2592 (Sotomayor, J. dissenting).
6 “We acknowledge the unfortunate hand that federal drug regulation has dealt Mensing, Demahy, and others similarly situated. But ‘it is not this Court’s task to decide whether the statutory scheme established by Congress is unusual or even bizarre.’” PLIVA, Inc. v. Mensing, 131 S. Ct. 2567, 2581-2 (2011)(footnote omitted).
8 On November 5, 2013, the FDA issued a proposed rule that addresses PLIVA. Noting that the Court found in PLIVA “that Federal law did not permit a generic drug manufacturer to … unilaterally strengthen warnings in its labeling or to issue additional warnings,” and because “the difference between [brand-name and generic companies’] ability to independently change product labeling … leads to different outcomes on whether Federal labeling requirements preempt State law failure-to-warn claims,” the proposed FDA rule would enable generic drug companies “to update product labeling promptly to reflect certain types of newly acquired information related to drug safety, irrespective of whether the revised labeling differs from” that of the brand-named drug. Under the rule, “when new information becomes available that causes information in labeling to be inaccurate,” a generic company “must take steps to change the content of its labeling.” U.S. Food and Drug Administration, “Supplemental Applications Proposing Labeling Changes for Approved Drugs and Biological Products,” Federal Register Doc. 2013-26799, November 13, 2013, at 67986-8, http://www.gpo.gov/fdsys/pkg/FR-2013-11-13/pdf/2013-26799.pdf
9 http://www.courts.ca.gov/opinions/documents/S233898.PDF
10 The Court also ruled that if the brand-name drug manufacturer’s failure to update its label foreseeably and proximately caused physical injury, the brand-name manufacturer’s liability does not automatically terminate when the manufacturer transfers its rights in the drug to another enterprise, in this case a “fly-by-night” company.
12 Ibid.
15 Ibid.
17 See https://www.shb.com/services/practices/public-policy
21 Id. at 578-9 (footnote omitted).
22 Id. at 579 (footnote omitted).
23 Id. at 579.
24 Ibid.